Sequenom Inc. Announces Participation At The J.P. Morgan 32nd Annual Healthcare Conference

SAN DIEGO, Jan. 6, 2014 /PRNewswire/ --Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the J.P. Morgan 32nd Annual Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California on January 13-16, 2014.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

Harry Hixson, Chairman and CEO, William Welch, President and COO, and Paul V. Maier, Chief Financial Officer, will present on Thursday, January 16, 2014 beginning at 2:00 p.m. PT, and provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be an audio webcast live through the "Invest" section of the Sequenom Web site at www.sequenom.com. An audio replay will be available for 90 days following the initial presentation.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostic markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

SOURCE Sequenom, Inc.